Background: Overexpression of erythropoietin (EPO) and EPO receptor (EPO-R) is associated with poor prognosis in non-small-cell lung carcinoma (NSCLC). Hypoxia, a potent EPO inducer, is a major stimulating factor in the growth of solid tumors. However, how EPO-R expression is regulated under hypoxia is largely unknown. Methods: The role of EPO-R in NSCLC cell proliferation was assessed by RNA interference in vitro. Luciferase reporter assays were performed to map the promoter elements involved in the EPO-R mRNA transcription. Nuclear co-immunoprecipitation and chromatin immunoprecipitation were performed to assess the interaction among transcription factors HIF1α, SP1, and EGR1 in the regulation of EPO-R under hypoxia. The expression of key EPO-R transcription factors in clinical specimens were determined by immunohistochemistry. Results: Hypoxia induced a dosage and time dependent EPO-R mRNA expression in NSCLC cells. Knockdown of EPO-R reduced NSCLC cell growth under hypoxia (P < 0.05). Mechanistically, a SP1-EGR1 overlapped DNA binding sequence was essential to the hypoxia induced EPO-R transcription. In the early phase of hypoxia, HIF1α interacted with EGR1 that negatively regulated EPO-R. With the exit of EGR1 in late phase, HIF1α positively regulated EPO-R expression through additive interaction with SP1. In clinical NSCLC specimen, SP1 was positively while EGR1 was negatively associated with active EPO-R expression (P < 0.05). Conclusions: HIF1α, SP1 and EGR1 mediated EPO-R expression played an essential role in hypoxia-induced NSCLC cell proliferation. Our study presents a novel mechanism of EPO-R regulation in the tumor cells, which may provide information support for NSCLC diagnosis and treatment. Graphical
Esophageal adenocarcinoma (EAC) is a rapidly increasing lethal tumor. It commonly arises from a metaplastic segment known as Barrett’s esophagus (BE), which delineates the at-risk population. Ample research has elucidated the pathogenesis of BE and its progression from metaplasia to invasive carcinoma; and multiple molecular pathways have been implicated in this process, presenting several points of cancer interception. Here, we explore the mechanisms of action of various agents, including proton pump inhibitors, non-steroidal anti-inflammatory drugs, metformin, and statins, and explain their roles in cancer interception. Data from the recent AspECT trial are discussed to determine how viable a multipronged approach to cancer chemoprevention would be. Further, novel concepts, such as the repurposing of chemotherapeutic drugs like dasatinib and the prevention of post-ablation BE recurrence using itraconazole, are discussed.
Background/Objectives: Esophageal squamous cell carcinoma (ESCC) is a predominant subtype of esophageal cancer in East Asia and is associated with high cancer-related mortality. CCAAT/enhancer-binding protein beta (CEBPB) is implicated in tumor progression and chemoresistance; however, its functional role and therapeutic potential in ESCC remain poorly understood. This study aimed to investigate the role of CEBPB in ESCC progression and cisplatin resistance and to explore its potential as a therapeutic target. Methods: CEBPB expression and its clinical significance were evaluated using public datasets and human ESCC tissue arrays. A human reflux model, esophageal organoids, and ESCC cell lines were used to investigate the effects of CEBPB on epithelial proliferation, differentiation, and cisplatin sensitivity. CEBPB gain- and loss-of-function experiments, apoptosis assays, pathway gene profiling and luciferase reporter assays were performed to assess its biological functions and transcriptional activity. The effects of combined cisplatin and itraconazole treatment were evaluated in ESCC cells. Statistical analyses were performed using unpaired t-tests or one-way ANOVA, and survival was analyzed using the Kaplan–Meier method and log-rank test. Results: In non-neoplastic esophageal tissues, increased CEBPB expression was associated with reflux-induced basal cell hyperplasia. Organoid experiments demonstrated that CEBPB promoted cell proliferation while suppressing basal cell differentiation. CEBPB expression was significantly elevated during ESCC progression, and higher expression was associated with poorer overall survival (P < 0.05). In cultured ESCC cells, CEBPB enhanced cell growth and survival by directly regulating the transcription of the anti-apoptotic gene MCL1. Elevated CEBPB expression conferred resistance to cisplatin, whereas CEBPB knockdown increased apoptosis and reduced MCL1 expression in cisplatin-resistant ESCC cells. Furthermore, combined treatment with cisplatin and itraconazole promoted apoptosis in cisplatin resistant and naïve ESCC cells compared with cisplatin treatment alone. Conclusions: CEBPB promotes ESCC progression and contributes to cisplatin resistance, at least in part, through transcriptional regulation of MCL1. Targeting CEBPB in combination with cisplatin may represent a potential therapeutic strategy for overcoming chemoresistance in ESCC and may have broader relevance across multiple cancer types in which CEBPB contributes to disease progression and drug resistance.